Long-term efficacy of hybrid pharmacologic and ablation therapy in patients with pilsicainide-induced atrial flutter

Clinical Cardiology

Volumn 28, Issue 7, 2005, Pages 338-342

  Hirao, Kenzo ^a,e   Okishige, Kaoru ^b   Yamamoto, Naohito ^c   Otomo, Kenichiro ^d   Azegami, Kouji ^a   Isobe, Mitsuaki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b YOKOHAMA CITY MINATO RED CROSS HOSPITAL   (Japan)

^c Souka City Hospital   (Japan)

^d Ohme City General Hospital   (Japan)

^e TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Atrial fibrillation; Atrial flutter; Catheter ablation; Class Ic drug; Hybrid therapy; Pilsicainide

Indexed keywords

ANTIARRHYTHMIC AGENT; PILSICAINIDE; POTASSIUM CHANNEL BLOCKING AGENT; SODIUM CHANNEL BLOCKING AGENT;

ADULT; AGED; ARTICLE; CATHETER ABLATION; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HEART ATRIUM FLUTTER; HUMAN; HYBRID THERAPY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NAUSEA; RASH; SINUS RHYTHM;

EID: 21344462121     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960280707     Document Type: Article

References (23)

1. Cheng TO: Atrial flutter during quinidine therapy of atrial fibrillation. Am Heart J 1956;52:273-289
2. Feld GH, Chen PS, Nicod P, Fleck RP, Mezer D: Atrial proarrhythmic effects of class IC antiarrhythmic drugs. Am J Cardiol 1990;66:378-382
3. Falk RH: Proarrhythmia in patients treated for atrial fibrillation or flutter. Ann Intern Med 1992;117:141-150
4. Friedman P, Stevenson WG: Proarrhythmia. Am J Cardiol 1998;82: 50N-58N
5. El-Harari MB, Adams PC: Atrial flutter with 1:1 atrioventricular conduction caused by propafenon. PACE 1998;21:1999-2001
6. Crijns HJ, van Gelder IC, Lie KI: Supraventricular tachycardia mimicking ventricular tachycardia during flecainide treatment. Am J Cardiol 1988;62: 1303-1306
7. Murdock CJ, Kyles AE, Lai-Wah JA, Qi A, Vorderbrugge S, Kerr CR: Atrial flutter in patients treated for atrial fibrillation with propafenone. Am J Cardiol 1990;66:755-757
8. Falk RH, Fogel RI: Flecainide. J Cardiovasc Electrophysiol 1994;5: 964-981
9. Kawabata M, Hirao K, Horikawa T, Suzuki K, Motokawa K, Suzuki F, Azegami K, Hiejima K: Syncope in patients with atrial flutter during treatment with class 1c antiarrhythmic drugs. J Electrocardiol 2001;34:65-72
10. Huang DT, Monahan KM, Zimetbaum P, Papageorgiou P, Epstein LM, Josephson ME: Hybrid pharmacologie and ablative therapy. A novel and effective approach for the management of atrial fibrillation. J Cardiovasc Electrophysiol 1998;9:462-469
11. Schumacher B, Jung W, Lewalter T, Vahlhaus C, Wolpert C, Luderitz B: Radiotrequency ablation of atrial flutter due to administration of class IC antiarrhythmic drugs for atrial fibrillation. Am J Cardiol 1999;83:710-713
12. Nabar A, Rodrigez LM, Timmermans C, Smeets JLRM, Wellens HJJ: Radiofrequency ablation of "class IC atrial flutter" in patients with resistant atrial fibrillation. Am J Cardiol 1999;83:785-787
13. Tai CT, Chiang CE, Lee SH, Chen YJ, Yu WC, Feng AN, Ding YA, Chang MS, Chen SA: Persistent atrial flutter in patients treated for atrial fibrillation with amiodarone and propafenone: Electrophysiologic characteristics, radiofrequency catheter ablation, and risk prediction. J Cardiovasc Electrophysiol 1999;10:1180-1187
14. Nabar A, Rodriguez LM, Timmermans C, van den Dool A, Smeets JLRM, Wellens HJJ: Effect of right atrial isthmus ablation on the occurrence of atrial fibrillation: Observations in four patient groups having type I atrial flutter with or without associated fibrillation. Circulation 1999;99:1441-1445
15. Reithmann C, Hoffmann E, Spitzlberger G, Dorwarth U, Gerth A, Remp T, Steinbeck G: Catheter ablation of atria! flutter due to amiodarone therapy for paroxysmal atrial fibrillation. Eur Heart J 2000;21:565-572
16. Reithmann C, Dorwarth U, Dugas A, Hahnefeld A, Ramamurthy S, Remp T, Steinbeck G: Risk factors for recurrence of atrial fibrillation in patients undergoing hybrid therapy for antiarrhythmic drug-induced atrial flutter. Eur Heart J 2003;24:1264-1272
17. Aisaka K, Hidaka T, Inomata N: N-(2,6-dimethylphenyl)-8- pyrrolizidineacetamide hydrochloride hemihydrate 8SUN 1165): A new potent and long-acting antiarrhythmic agent. Arzneimittelforschung/Drug Res 1985;35: 1239-1245
18. Hattori Y, Inomata N, Aisaka T, Ishikawa T: Electrophysiological action of N-(2,6-dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate (SUN 1165), a new antiarrhythmic agent. J Cardiovasc Pharmacol 1986;8:998-1002
19. Ino T, Atarashi H, Hayakawa H: Electrophysiologic and hemodynamic effects of SUN 1165, a new antiarrhythmic agent. In Current Topics in Antiarrhythmic Agents, p. 219 (Eds: Toyama J, Hondeghem LM), Tokyo: Excepta Medica, 1989
20. Atarashi H, Inoue H, Hiejima K, Hayakawa H: Conversion of recent-onset atrial fibrillation by a single oral dose of pilsicainide (pilsicainide Suppression Trial on Atrial Fibrillation). Am J Cardiol 1996;78:694-697
21. Okishige K, Nishizaki M, Azegami K, Igawa M, Yamawaki N, Aonuma K, and the Kanagawa Arrhythmia Task Force Investigators: Pilsicainide for conversion and maintenance of sinus rhythm in chronic atrial fibrillation: A placebo-controlled, multicenter study. Am Heart J 2000;140:437-444
22. Stabile G, Simone AD, Turco P, Rocca VL, Nocerino P, Astarita C, Maresca F, Matteis CD, Napoli TD, Stabile E, Vitale DF: Response to flecainide infusion predicts long-term success of hybrid pharmacologic and ablation therapy in patients with atrial fibrillation. J Am Coll Cardiol 2001;37: 1639-1644
23. Schumacher B, Spehl S, Haase KK, Pfleger S, Wolpert C, Juncker M, Gaudron P, Jung W, Luderitz B: "Hybrid" therapy of atrial fibrillation: Patients selection by IV administration of class 1c antiarrhythmic drugs. Preliminary results of a prospective randomized trial. PACE 2000;23:II-651